Clinical Trial Update: Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating NMS-03592088 in relapsed or refractory acute myeloid leukemia and chronic myelomonocytic leukemia has terminated with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• NMS-03592088

Snippet

Sponsor: Nerviano Medical Sciences | Conditions: Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-03-18